Treatment of Prostatic Cancer with Diethylstilboestrol — Detection and Evaluation of the Vascular Risk

  • C. C. Abbou
  • V. Beaumont
  • D. Chopin
  • J. P. Deburge
  • J. L. Beaumont
  • J. Auvert
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


A retrospective study of patients suffering from prostatic cancer and treated with estrogens has allowed us to develop a test to discriminate a population with a high risk of thrombotic complications due to estrogens from a population that can benefit without danger from this form of hormonal therapy. The so-called “estrogen tolerance test” relies on the presence of circulating immune complexes which can be precipitated from serum by 25% saturated ammonium sulphate.

In the group of patients in which immune complexes exceeded 700μg/ml, 41% developed thrombo-embolic complications including embolism and arterial thrombosis. The group of patients in whom the values were under 300 μg/ml had a lower risk of arterial thrombosis (2.5%) and the observed incidents were benign and mostly venous thrombosis.

Test values above 700 μg/ml should preclude treatment with diethylstilboestrol.


Prostatic Cancer Oral Contraceptive Venous Thrombosis Immune Complex Arterial Thrombosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D.P. Byar, Treatment of prostatic cancer: studies by the Veterans Administration Cooperative Urological Research Group, Bull. N.Y. Acad. Med. 48: 751 (1972).PubMedGoogle Scholar
  2. 2.
    Collaborative Group for the Study of Stroke in Young Women, Oral contraception and increased risk of cerebral ischemia or thrombosis, N. Engl. J. Med. 288: 871 (1973).CrossRefGoogle Scholar
  3. 3.
    J.I. Mann, M.C. Vessey, M. Thorogood, and A. Doll, Myocardial infarction in young women with special reference to oral contraceptive practice, Br. Med. J. 2: 241 (1975).PubMedCrossRefGoogle Scholar
  4. 4.
    Report from the Boston Collaborative Drug Surveillance Program, Oral contraceptives and venous thrombo-embolic diseases, surgically confirmed gall-bladder disease and breast tumors, Lancet 1: 1399 (1973).Google Scholar
  5. 5.
    J.L. Beaumont and N. Lemort, Oral contraceptives, pulmonary artery thrombosis and anti-ethinyl-oestradiol monoclonal IgG, Clin. Exper. Immunol. 24: 455 (1976).Google Scholar
  6. 6.
    V. Beaumont, L. Lorenzelli-Edouard, N. Lemort, and J.L. Beaumont, Composition of circulating immune complexes induced by oral contraceptives, Biomedicine 30: 256 (1979).PubMedGoogle Scholar
  7. 7.
    J.L. Beaumont, N. Lemort, L. Lorenzelli, B. Delplanque, and V. Beaumont, Antiethinylestradiol antibody activities in oral contraceptive users, Clin. Exper. Immunol. 38: 445 (1979).Google Scholar
  8. 8.
    V. Beaumont, N. Lemort, L. Lorenzelli, A. Mosser, and V. Beaumont, Hormones contraceptives, risque vasculaire et précipit-abilité anormale des gamma-globulines sériques, Pathol. Biol. 26: 531 (1978).PubMedGoogle Scholar
  9. 9.
    R.P. Doe and C.E. Blackard, Incidence of cardiovascular disease and death in patients receiving diethyl-stilbestrol for carcinoma of the prostate, Cancer 26: 249 (1970).PubMedCrossRefGoogle Scholar
  10. 10.
    J.A. Heaney and H.C. Chang, Prognosis of clinically undiagnosed prostatic carcinoma and the influence of endocrine therapy, J. Urol. 118: 283 (1977).PubMedGoogle Scholar
  11. 11.
    E.F. Hawkins and M. Nijs, Steroid receptors in the human prostate. Detection of tissue-specific androgen binding in prostate cancer, Clin. Chim Acta 75: 303 (1977).PubMedCrossRefGoogle Scholar
  12. 12.
    C. Huggins and C.V. Hodges, Studies on prostatic cancer, Cancer Res. 1: 293 (1941).Google Scholar
  13. 13.
    A.C. Jackson and M. Tenniswood, Effects of androgen and estradiol administration on the weights of the central prostate, seminal vesicles and testes of immature rats, Invest. Urol. 14: 351 (1977).PubMedGoogle Scholar
  14. 14.
    M.W. Woodruff, The effect of estrogen and androgen on the rat prostate gland and testes, J. Urol. 84: 162 (1960).PubMedGoogle Scholar
  15. 15.
    M.W. Woodruff, The effect of hormonal modification on prostatic morphology, J. Urol. 88: 273 (1962).PubMedGoogle Scholar
  16. 16.
    J.D. Young and N. Bashirelahi, Specific binding protein for 17-beta-estradiol in prostate with adenocarcinoma, Urology 8: 553 (1976).PubMedCrossRefGoogle Scholar
  17. 17.
    P.H. Beck and W.J. McAninch, Plasma testosterone in patients receiving diethylstilbestrol, Urology 11: 157 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    R.K. Kanis, G. Lasry, D. Melliere, V. Beaumont, and H. Botto, Thrombose aigue artérielle sévère sous oestrogénothérapie à forte dose, Nouv. Presse Méd. 7: 2396 (1978).Google Scholar
  19. 19.
    L. Irey, W.C. Havion, and H.B. Taylor, Vascular lesions in women taking oral contraceptives, Arch. Pathol. 89: 1 (1970).PubMedGoogle Scholar
  20. 20.
    F.J. Dixon, J.D. Feldman, and J.J. Vasquez, Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis, J. Exper. Med. 113: 899 (1961).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • C. C. Abbou
    • 1
  • V. Beaumont
    • 1
  • D. Chopin
    • 1
  • J. P. Deburge
    • 1
  • J. L. Beaumont
    • 1
  • J. Auvert
    • 1
  1. 1.Hôpital Henri-MondorCreteilFrance

Personalised recommendations